In this special edition of Diabetes Core Update, host Neil Skolnik, MD, explores the timely and critical topic of compounded medications in diabetes care. In this episode Dr. Skolnik moderates a discussion between a family doctor, a patient, and a pharmacist about practical decision making around the topic of compounded medication for the treatment of overweight and obesity.

This special edition of Diabetes Core Update is supported by Lilly.

Presented by:

• Neil Skolnik, MD – Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington–Jefferson Health
• John Hertig, PharmD, MS, CPPS – Associate Professor, Butler University College of Pharmacy and Health Sciences
• Susan Kuchera, MD - Clinical Assistant Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University and Program Director of the Family Medicine Residency at Jefferson Health Abington.
• Lisa Kessler MS, CCC-SLP - Infant-toddler Homebased Pediatric Speech-Language Pathologist

Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care December 2, 2024; dci240091 https://doi.org/10.2337/dci24-0091 PubMed: 39620926

FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. US FDA Website ( current as of 12/18/2024)